Gareth has joined Arcinova from Britest, a manufacturing process consultancy, where he was chief executive officer. His experience includes research, development, scale-up and commercialisation spanning laboratory, kilo-lab, pilot and commercial plant scales.
 
In his new role, Gareth will focus on identifying technology that will enable Arcinova to further enhance its innovation-led approach to pharmaceutical development. An initial area of focus will be to drive Arcinova’s adoption of flexible, modular continuous manufacturing processes. In doing so, the organisation and its customers will continue to benefit from streamlined efficiencies in keeping with Arcinova’s agile approach to drug development. Another key element of Gareth’s role will be to harness the power of biology – and in particular the growing field of synthetic biology – to access complex, novel materials from simple, sustainable resources. 
  
Dr Gareth Jenkins said, “I’m looking forward to supporting the continued expansion of Arcinova. The company has seen impressive growth over the last two years and I feel that I am coming on board at an exciting phase in its development. Arcinova’s commitment to innovation closely aligns with my passion for industrial biotechnology, synthetic biology and continuous manufacturing and process engineering.”
 
Ian Shott, executive chairman and managing director of Arcinova, said, “I first worked with Gareth in 2005 when I was CEO of Excelsyn, a pharmaceutical development and manufacturing services company. I am therefore delighted to be able to welcome Gareth to the Arcinova team – and to be working with him again.”
 
Arcinova recently announced the award of a £1.5 million Innovate UK grant for the development of new flexible modular manufacturing technologies, a project which is set to demonstrate the operating feasibility of world first innovative continuous production tools.